Enterprise development
JunRui Biotechnology has developed a series of small molecule antagonists targeting CXCR4 / CXCL12 signal axis as novel therapies against cancer. The leading compounds have shown superior in vivo efficacy resulted from better PK and ADME properties. Junrui Biotechnology will pursue more vibrant R & D programs in the future through internal discovery and external collaborations.
